Unlike supportive treatment, eculizumab specifically targets the complement C5 protein and thereby prevents complement activation, reducing intravascular hemolysis, thrombosis, and other complications and symptoms in PNH. This evidence concerns the gene C5 and paroxysmal nocturnal hemoglobinuria.